Full text is available at the source.
Abstract
The median relative expression level of MGMT was 4.29 among nine patients with relapsed or refractory brain tumors treated with oral temozolomide.
- Insufficient response to oral temozolomide in children with brain tumors may be influenced by the DNA repair mechanism of MGMT.
- MGMT levels were analyzed using qRT-PCR and immunohistochemistry in patients enrolled in an off-label trial.
- Six of the nine tumor samples scored 2+ for MGMT expression, while three scored 1+, and none were MGMT negative.
- Methylation of the MGMT promoter was detected in only one ependymoma sample.
- The varied progression-free survival among patients suggests that MGMT expression alone does not predict the response to temozolomide.
Simplified